• Andrew Berens from Leerink Partners set a price target of $37 for NASDAQ:ZYME, indicating a potential increase of approximately 54.81%.
• Ziihera, developed in collaboration with Jazz Pharmaceuticals, shows significant improvement in treating HER2-positive gastroesophageal adenocarcinoma.
• ZYME's market capitalization stands at approximately $1.8 billion, with a trading volume of 11.1 million shares, reflecting increased investor interest.

Zymeworks Inc. (NASDAQ:ZYME) is a biotechnology company focused on developing multifunctional therapeutics, primarily for cancer treatment. The company collaborates with other pharmaceutical firms to advance its drug pipeline. A notable competitor in the biotech space is Jazz Pharmaceuticals, with whom Zymeworks has partnered for drug development.

On November 17, 2025, Andrew Berens from Leerink Partners set a price target of $37 for ZYME. At that time, the stock was priced at $23.90, suggesting a potential increase of approximately 54.81%. This optimistic outlook is supported by recent successful phase 3 results for Ziihera, a drug developed in collaboration with Jazz Pharmaceuticals.

Ziihera, when combined with chemotherapy, has shown significant improvement in treating HER2-positive gastroesophageal adenocarcinoma. This success positions Zymeworks to benefit from royalties, as highlighted by the market opportunity exceeding $2 billion annually for Jazz Pharmaceuticals and $300 million for BeOne. This development could positively impact ZYME's stock performance.

Currently, ZYME is trading at $23.90, reflecting a 29.05% increase with a $5.38 change. The stock has fluctuated between $22.55 and $26.19 today, with the latter being its highest price over the past year. The lowest price for the year was $9.03, indicating significant growth potential.

ZYME's market capitalization stands at approximately $1.8 billion, with a trading volume of 11.1 million shares today. This increased activity suggests heightened investor interest, likely driven by the promising phase 3 results and the potential financial benefits from the Ziihera collaboration.